Luminex Hosting Planet xMAP - Analyst Blog
29 September 2011 - 1:49AM
Zacks
Luminex Corporation (LMNX), a developer of
biological testing technologies, will host its annual European
multiplexing technology symposium in Vienna, Austria, on September
28-29. The event, called “Planet xMAP Europe 2011,” will feature
scientific sessions, workshops, discussion groups and exhibitions,
among others.
Scientists
and researchers across the planet who have been conducting
clinical diagnostics and life science research using the company’s
popular Luminex xMAP multiplexing platform will gather and exchange
ideas on this breakthrough technology at the annual symposium.
Luminex noted that focused areas of Planet xMAP Europe 2011 will
include pathogen detection, immunology-monitoring, human genetics,
protein and nucleic acid research.
The event will feature two days of presentations with focused
sessions. The focused areas on the first day (or September 28) will
be pathogen detection, the xTAG Gastrointestinal Pathogen Panel
(“GPP”) molecular test, immunology-monitoring and human genetics.
The second day (or September 29) will focus on genomic and protein
research.
The cynosure of the symposium will be the xTAG GPP molecular
diagnostic platform. Luminex received the European CE mark approval
for xTAG GPP in May 2011. Based on the company’s proprietary xMAP
multiplexing platform, the novel molecular test allows fast and
simultaneous detection of 95% of bacterial, viral and
gastroenteritis pathogens in a single test. xTAG GPP was used to
detect the outbreak-causing E. coli strain (Shiga toxin producing
E. coli/STEC strain) in Germany.
Texas-based Luminex develops and markets proprietary biological
testing technologies, which have applications across the life
sciences industry. Its proprietary open-architecture xMAP
technology enables fast, cost-effective and accurate conduct
and analyses
of biological tests (bioassays). The company competes with
Affymetrix (AFFX) and Sequenom
(SQNM), among others.
Luminex continues to expand its xMAP technology-based installed
instrument base. The company shipped 248 analyzers (including 62
MAGPIX analytical instruments) in second- quarter 2011, resulting
in total shipments of 8,145 analyzers, up 13% year over year.
Luminex possesses an extensive product portfolio and a healthy
pipeline of novel assays, which are expected to support growth
going ahead. However, the company is challenged by sluggish growth
in its core markets, faces regulatory uncertainties, and depends
heavily on partners to market its instruments and assays, a
strategy that
has inherent risks. We are currently Neutral on the
stock.
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
LUMINEX CORP (LMNX): Free Stock Analysis Report
SEQUENOM INC (SQNM): Free Stock Analysis Report
Zacks Investment Research
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024